Publications en collaboration avec des chercheurs de Instituto de Investigación Biomédica de Salamanca (16)

2023

  1. Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data

    Cancers, Vol. 15, Núm. 17

  2. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis

    Chinese Clinical Oncology, Vol. 12, Núm. 6

2022

  1. Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review

    Current Problems in Cancer: Case Reports, Vol. 6

  2. Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy

    Frontiers in bioscience (Landmark edition), Vol. 27, Núm. 3, pp. 88

  3. Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis

    Biomedicines, Vol. 10, Núm. 2

2021

  1. Head and neck cancer

    Medicine (Spain), Vol. 13, Núm. 25, pp. 1393-1401

  2. Immunotherapy in lung cancer

    Medicine (Spain), Vol. 13, Núm. 25, pp. 1424-1428

  3. Mesothelioma

    Medicine (Spain), Vol. 13, Núm. 25, pp. 1402-1408

  4. Molecular and cellular biomarkers. Implications for targeted therapy

    Medicine (Spain), Vol. 13, Núm. 25, pp. 1418-1423

  5. Non-small cell lung cancer

    Medicine (Spain), Vol. 13, Núm. 25, pp. 1377-1387

  6. Paciente gran superviviente con cáncer de cabeza y cuello metastásico y tratamiento con inmunoterapia

    Medicine (Spain), Vol. 13, Núm. 25, pp. 1429.e1-1429.e3

  7. Small cell lung cancer

    Medicine (Spain), Vol. 13, Núm. 25, pp. 1369-1376

  8. Therapeutic and palliative indications of radiotherapy in lung and thoracic tumors

    Medicine (Spain), Vol. 13, Núm. 25, pp. 1409-1413

  9. Therapeutic and palliative indications of surgery in lung and thoracic tumors

    Medicine (Spain), Vol. 13, Núm. 25, pp. 1414-1417

  10. Thymic epithelial tumors. Thymoma

    Medicine (Spain), Vol. 13, Núm. 25, pp. 1388-1392

  11. Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma

    The American Journal of dermatopathology, Vol. 43, Núm. 6, pp. 423-428